Novartis
East Hanover, New Jersey, 07936, United States
NCT Number: NCT07450157
The aim of this study was to evaluate patient characteristics, treatment patterns, prostate-specific antigen (PSA) reduction, and overall survival (OS) of prostate cancer patients treated with 177-Lutetium-Prostate-Specific Membrane Antigen-617 (177Lu-PSMA-617). Patient data from multiple electronic health record databases, including claims (open-source medical and pharmacy claims), consumer attributes, mortality, and laboratory data linked to claims databases was used.
The study analysis was conducted in two phases. Phase I provided an early view of patients treated with 177Lu-PSMA-617 shortly after launch. Phase II refreshed the data, added mortality and extracted additional years of historical data to allow for the identification of the initial metastatic castrate-resistant prostate cancer (mCRPC) diagnosis and follow-up from that date through the start of 177Lu-PSMA-617.
Looking for future studies?
Notify Me18 year and older
Male
Observational
East Hanover, New Jersey, 07936, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Phase I inclusion criteria:
For the treatment response analysis, the following additional criteria were applied:
Phase II inclusion criteria:
Exclusion criteria
Time frame: Baseline
Demographics included:
Time frame: Baseline
Clinical characteristics included:
Time frame: Baseline
Time frame: Up to approximately 10 years
OS was defined as the time from mCRPC diagnosis until death.
Time frame: 6, 12, 24, and 36 months
Time frame: Up to approximately 10 years
Time frame: Up to approximately 10 years
Time frame: Up to approximately 10 years
Time frame: Up to approximately 10 years
Time frame: Baseline
Time frame: Up to approximately 10 years
Time frame: Up to approximately 10 years
Time frame: Up to approximately 10 years
Time frame: 3, 6, 9, and 12 Months
Time frame: Up to approximately 10 years
Time frame: Up to approximately 10 years
TTNT was defined as time from the start of 177Lu-PSMA-617 therapy to the initiation of a new LOT.
Time frame: Up to approximately 2 years
Reduction in PSA was categorized as ≥50%, ≥80%, and ≥90%.
Novartis Pharmaceuticals
Industry
Patient Characteristics, Treatment Patterns and Outcomes Among Early Adopters of 177Lu-PSMA-617: An Early View Claims Data Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03269422
Genital Diseases, Genital Diseases, Male
Basking Ridge, New Jersey, United States
View Trial DetailsNCT05754658
Breast Cancer, Breast Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT03606837
Genital Diseases, Genital Diseases, Male
Bordeaux, France
View Trial DetailsNCT06540794
Genital Diseases, Genital Diseases, Male
Istanbul, Turkey (Türkiye)
View Trial Details